Table:
Participant characteristics
| Crohn’s disease (N=165) | Ulcerative/indetermin ate colitis (N=81) |
Total (N=246) | |
|---|---|---|---|
| Age at Enrollment | |||
| Mean (SD) | 48.1 (16.1) | 46.1 (14.4) | 47.4 (15.5) |
| Median [Min, Max] | 45.0 [20.0, 85.0] | 43.0 [22.0, 79.0] | 44.0 [20.0, 85.0] |
| Sex | |||
| Male | 56 (33.9%) | 33 (40.7%) | 89 (36.2%) |
| Female | 96 (58.2%) | 43 (53.1%) | 139 (56.5%) |
| Prefer not to answer | 1 (0.6%) | 0 (0%) | 1 (0.4%) |
| Self Reported Race | |||
| White | 139 (84.2%) | 62 (76.5%) | 201 (81.7%) |
| Black or African American | 5 (3.0%) | 0 (0%) | 5 (2.0%) |
| Asian | 2 (1.2%) | 6 (7.4%) | 8 (3.3%) |
| Native Hawaiian or other Pacific Islander | 0 (0%) | 0 (0%) | 0 (0%) |
| American Indian/ Alaska Native | 0 (0%) | 1 (1.2%) | 1 (0.4%) |
| Multiple | 3 (1.8%) | 1 (1.2%) | 4 (1.6%) |
| Other | 3 (1.8%) | 6 (7.4%) | 9 (3.7%) |
| Prefer not to answer | 1 (0.6%) | 0 (0%) | 1 (0.4%) |
| Self-Reported Hispanic Ethnicity | |||
| Hispanic/LatinX | 6 (3.6%) | 1 (1.2%) | 7 (2.8%) |
| Non-Hispanic/LatinX | 147 (89.1%) | 75 (92.6%) | 222 (90.2%) |
| Prefer not to answer | 0 (0%) | 0 (0%) | 0 (0%) |
| BMI | |||
| Mean (SD) | 25.5 (6.39) | 25.6 (5.74) | 25.6 (6.17) |
| Median [Min, Max] | 23.7 [15.5, 67.3] | 23.6 [18.1, 44.5] | 23.7 [15.5, 67.3] |
| Ever Smoked | |||
| Yes | 21 (12.7%) | 16 (19.8%) | 37 (15.0%) |
| No | 100 (60.6%) | 51 (63.0%) | 151 (61.4%) |
| Currently Smokes | |||
| Yes | 0 (0%) | 0 (0%) | 0 (0%) |
| No | 21 (12.7%) | 16 (19.8%) | 37 (15.0%) |
| Month of Enrollment | |||
| Dec, 2020 | 3 (1.8%) | 1 (1.2%) | 4 (1.6%) |
| Jan, 2021 | 19 (11.5%) | 8 (9.9%) | 27 (11.0%) |
| Feb, 2021 | 52 (31.5%) | 33 (40.7%) | 85 (34.6%) |
| Mar, 2021 | 91 (55.2%) | 39 (48.1%) | 130 (52.8%) |
| Vaccine Type | |||
| BNT162 (Pfizer/BioNtech) | 93 (56.4%) | 48 (59.3%) | 141 (57.3%) |
| mRNA-1273 (Moderna/NIH) | 72 (43.6%) | 33 (40.7%) | 105 (42.7%) |
| Prior COVID Infection | |||
| No | 146 (88.5%) | 70 (86.4%) | 216 (87.8%) |
| Yes | 4 (2.4%) | 5 (6.2%) | 9 (3.7%) |
| Age at IBD Diagnosis | |||
| Mean (SD) | 28.3 (15.4) | 30.7 (12.9) | 29.1 (14.6) |
| Median [Min, Max] | 25.0 [4.00, 85.0] | 28.0 [8.00, 64.0] | 26.0 [4.00, 85.0] |
| Duration (years) of IBD | |||
| Mean (SD) | 19.5 (14.6) | 15.6 (11.9) | 18.2 (13.8) |
| Median [Min, Max] | 16.0 [0, 61.0] | 13.0 [0, 49.0] | 15.0 [0, 61.0] |
| Prior Vaccine Adverse Reaction | |||
| Yes | 7 (4.2%) | 4 (4.9%) | 11 (4.5%) |
| No | 157 (95.2%) | 74 (91.4%) | 231 (93.9%) |
| Not sure | 1 (0.6%) | 3 (3.7%) | 4 (1.6%) |
| Sulfasalazine/mesalamine | |||
| Yes | 25 (15.2%) | 33 (40.7%) | 58 (23.6%) |
| No | 132 (80.0%) | 46 (56.8%) | 178 (72.4%) |
| Budesonide | |||
| Yes | 4 (2.4%) | 2 (2.5%) | 6 (2.4%) |
| No | 153 (92.7%) | 77 (95.1%) | 230 (93.5%) |
| Oral/parenteral steroids | |||
| Yes | 12 (7.3%) | 5 (6.2%) | 17 (6.9%) |
| No | 145 (87.9%) | 74 (91.4%) | 219 (89.0%) |
| 6MP/azathioprine monotherapy | |||
| Yes | 4 (2.4%) | 2 (2.5%) | 6 (2.4%) |
| No | 153 (92.7%) | 77 (95.1%) | 230 (93.5%) |
| Methotrexate monotherapy | |||
| Yes | 0 (0%) | 0 (0%) | 0 (0%) |
| No | 157 (95.2%) | 79 (97.5%) | 236 (95.9%) |
| Anti-TNF without 6MP/AZA/MTX | |||
| Yes | 51 (30.9%) | 18 (22.2%) | 69 (28.0%) |
| No | 106 (64.2%) | 61 (75.3%) | 167 (67.9%) |
| Anti-TNF + 6MP/AZA/MTX | |||
| Yes | 12 (7.3%) | 9 (11.1%) | 21 (8.5%) |
| No | 145 (87.9%) | 70 (86.4%) | 215 (87.4%) |
| Anti-integrin | |||
| Yes | 25 (15.2%) | 8 (9.9%) | 33 (13.4%) |
| No | 132 (80.0%) | 71 (87.7%) | 203 (82.5%) |
| IL12/23 inhibitor | |||
| Yes | 37 (22.4%) | 4 (4.9%) | 41 (16.7%) |
| No | 120 (72.7%) | 75 (92.6%) | 195 (79.3%) |
| JAK inhibitor | |||
| Yes | 1 (0.6%) | 3 (3.7%) | 4 (1.6%) |
| No | 156 (94.5%) | 76 (93.8%) | 232 (94.3%) |
| 5-ASA, oral or rectal | |||
| Yes | 25 (15.2%) | 33 (40.7%) | 58 (23.6%) |
| No | 132 (80.0%) | 46 (56.8%) | 178 (72.4%) |
| Other | |||
| Yes | 8 (4.8%) | 3 (3.7%) | 11 (4.5%) |
| No | 149 (90.3%) | 76 (93.8%) | 225 (91.5%) |
| Any steroids | |||
| No | 137 (83.0%) | 69 (85.2%) | 206 (83.7%) |
| Yes | 20 (12.1%) | 10 (12.3%) | 30 (12.2%) |
| Any Biologic | |||
| No | 31 (18.8%) | 37 (45.7%) | 68 (27.6%) |
| Yes | 126 (76.4%) | 42 (51.9%) | 168 (68.3%) |
| Any immunomodulator | |||
| No | 134 (81.2%) | 67 (82.7%) | 201 (81.7%) |
| Yes | 23 (13.9%) | 12 (14.8%) | 35 (14.2%) |
| No immune-modifying therapies | |||
| No | 136 (82.4%) | 50 (61.7%) | 186 (75.6%) |
| Yes | 21 (12.7%) | 29 (35.8%) | 50 (20.3%) |